COMMUNIQUÉS West-GlobeNewswire

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
01/09/2026
Enrollment completed in KT-621 BROADEN2 Phase 2b AD trial with topline data expected by year-end 2026; Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with topline data [...]
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
01/09/2026
WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' [...]
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
01/09/2026
Data to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797S BH-30643 was recently granted Fast Track designation by [...]
Remix Therapeutics to Participate in Upcoming Investor Conferences
01/09/2026
WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying [...]
Syndax Announces Participation in September Investor Conferences
01/09/2026
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief [...]
AAVantgarde appoints Megan Zoschg Canniere as Chief Regulatory & Quality Officer
01/09/2026
MILAN, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs) with clinical programs in Usher syndrome type 1B [...]
NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier
01/09/2026
Pharmaceutical industry leader brings more than 20 years of global drug development, regulatory strategy and portfolio leadership experience across AbbVie, Merck KGaA, AstraZeneca and Abivax TORONTO, Sept. 01, 2026 ( [...]
Harrow to Participate in Three Investor Conferences in September
01/09/2026
NASHVILLE, Tenn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the [...]
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
01/09/2026
– Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indication – – The [...]
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®
01/09/2026
Together with the previously announced Talicia strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that [...]
The Insides Company franchit une nouvelle étape vers le remboursement de son dispositif médical The Insides System® en France
01/09/2026
La Haute Autorité de Santé rend un avis favorable à l’inscription de The Insides System® sur la Liste des Produits et Prestations Remboursables (LPPR), franchissant une étape décisive vers une prise en charge pérenne [...]
Boehringer Ingelheim launches SCOVELLA® in Great Britain, the first approved therapy for insulin dysregulation in horses, a main cause of laminitis
01/09/2026
Ingelheim, Germany, and Bracknell, United Kingdom SCOVELLA® is the first therapy specifically developed and approved for the treatment of hyperinsulinemia in insulin-dysregulated horses and ponies 1 , targeting the key [...]
Transactions in connection with share buy-back program
01/09/2026
Company announcement no. 33 - 26 01 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
ENA Respiratory Awarded Biointelect Venturer Funding to Support New Study in Asthma Patients of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
01/09/2026
MELBOURNE, Australia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing host defence enhancers for the prevention of complications associated with respiratory viral [...]
Resolution Therapeutics partners with the Blood Centers of America, Inc. to support broad patient access to its experimental Regenerative Macrophage Therapy in the U.S.
01/09/2026
Partnership will support Resolution’s pivotal clinical program in 2027, as well as future commercial preparedness for RTX001, its lead asset in patients with end-stage liver disease (ESLD) Primary goal is to ensure [...]
Bavarian Nordic Launches First Tranche of New Share Buy-Back Program
01/09/2026
COPENHAGEN, Denmark, September 1, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the first tranche of the new share buy-back program announced on August 21, under which the Company intends to repurchase own [...]
Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
01/09/2026
Ad hoc announcement pursuant to Art. 53 LR REMODEL-1/-2 trials met their primary endpoint, significantly reducing annualized relapse rate (ARR) vs teriflunomide in people living with relapsing multiple sclerosis (RMS) 1 [...]
argenx to Present at Upcoming Investor Conferences
01/09/2026
September 1, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor [...]
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
01/09/2026
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule [...]

Pages